Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2006 Financial Results.

DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to report third quarter 2006 financial results on Tuesday, November 7, 2006 before the market opens. Inspire's President and CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host a conference call and live webcast on November 7, 2006 at 10:00 a.m. ET.

To access the conference call, U.S. participants may call [phone] and international participants may call [phone]. The conference ID number is 7996513. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until November 21, 2006. To access this replay, U.S. participants may call [phone] and international participants may call [phone]. The conference ID number is 7996513.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat([R]) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis([R]) (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.